Clinical Trials Browser

Phase 2 × Fallopian Tube Neoplasms × tisotumab vedotin × Clear all

NCT03657043 2023-05-06

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Phase 2 Completed

98 enrolled 30 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms